A5046936406- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- COVID-19 Clinical Research Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Long-Term Effects of COVID-19
- Respiratory Support and Mechanisms
- SARS-CoV-2 and COVID-19 Research
- Inhalation and Respiratory Drug Delivery
- Tracheal and airway disorders
- Transplantation: Methods and Outcomes
- Intensive Care Unit Cognitive Disorders
- Occupational and environmental lung diseases
- Pneumothorax, Barotrauma, Emphysema
- Renal Transplantation Outcomes and Treatments
- COVID-19 and healthcare impacts
- Polyomavirus and related diseases
- Antibiotic Resistance in Bacteria
- Pleural and Pulmonary Diseases
- Parasites and Host Interactions
- Central Venous Catheters and Hemodialysis
- Pediatric health and respiratory diseases
- Antibiotics Pharmacokinetics and Efficacy
- Medical Imaging and Pathology Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Cell Adhesion Molecules Research
University of Michigan
2007-2025
META Group
2025
Analysis Group (United States)
2025
National Heart Lung and Blood Institute
2023-2024
Michigan United
2019-2023
Canadian Respiratory Research Network
2023
Yale University
2023
Yale Cancer Center
2023
Rush Children's Hospital
2023
Rush University Medical Center
2023
Progressive fibrosis is a complication of many chronic diseases, and collectively, organ the leading cause death in United States. Fibrosis characterized by accumulation activated fibroblasts excessive deposition extracellular matrix proteins, especially type I collagen. Extensive research has supported role for signaling propagating fibrosis, but collagen itself often considered an end product rather than important regulator continued deposition. Type can activate several cell surface...
Progressive pulmonary fibrosis is a devastating consequence of many acute and chronic insults to the lung. Lung injury leads alveolar epithelial cell (AEC) death, destruction basement membrane, activation transforming growth factor-β (TGF-β). There subsequent resolution coordinated concurrent initiation fibrosis. Both these processes may involve similar intracellular signaling pathways regulated in part by dynamic changes extracellular matrix. Matrix can augment profibrotic fibroblast...
ABSTRACT Objective Although studies have examined changes in C‐reactive protein (CRP) during pulmonary exacerbations (PEX) people with cystic fibrosis (PwCF), few evaluated CRP profiles across age groups. Here, we characterize age‐related responses to PEX treatment. Methods We measured concentrations at the beginning and end of intravenous (IV) antibiotic therapy for 100 pediatric 147 adult PwCF 10 US CF Centers. relationships between age, lung function, severity symptoms, time next PEX....
Abstract Introduction Impaired plasminogen activation (PA) is causally related to the development of lung fibrosis. Prior studies demonstrate that enhanced PA in limits severity scarring following injury and vitro indicate promotes matrix degradation fibroblast apoptosis. These findings led us hypothesize increased an vivo model would enhance resolution established fibrosis conjunction with myofibroblast Methods Transgenic C57BL/6 mice doxycycline inducible lung-specific urokinase activator...
Fibrosis is characterized by fibroblast activation, leading to matrix remodeling culminating in a stiff, type I collagen-rich fibrotic matrix. Alveolar epithelial cell (AEC) apoptosis also major feature of fibrogenesis, and AEC sufficient initiate robust lung response. TGF-β (transforming growth factor-β) driver fibrosis can induce both activation. We others have previously shown that changes extracellular stiffness composition regulate the cellular response TGF-β. In present study, we find...
The optimal polymyxin B dosage needed to achieve an efficacy target of 50 100 mg · h/liter when treating multidrug-resistant bacterial infections in adult cystic fibrosis (CF) patients is unclear. pharmacokinetics intravenous were evaluated better inform dosing.
The unprecedented public health burdens of coronavirus disease (COVID-19) have intensified the urgency identifying effective, low-cost treatments that limit need for advanced life support measures and improve clinical outcomes. However, personal protective equipment staffing shortages, virulence, infectivity created significant barriers to traditional trial practices. We present novel design a pragmatic, adaptive, multicenter, international, prospective randomized controlled evaluating...
Lung transplant (LTx) saves lives in cystic fibrosis (CF). However, many potential candidates express uncertainty about LTx and die before receiving this treatment. CF guidelines recommend education clinical discussions well the need for arises, but limited patient resources exist.We engaged people with physicians human-centered design of "Take On Transplant" (TOT), a web-based tool to prepare patients discussions. Across 3 phases, needs assessment, groups, iterative user testing TOT, we...